SCHEMBL5165585

SCHEMBL5165585

CN(CCc1c[nH]c2ccccc12)C1CCC(c2ccccc2)(N(C)C)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 8/20 0.69
OPRM1 P35372 7/20 0.68
HTR1A P08908 3/20 0.53
HTR2A P28223 3/20 0.53
HTR2C P28335 2/20 0.53
HTR2B P41595 2/20 0.53
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
MAPT P10636 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
BCHE P06276 1/20 0.50
HTR6 P50406 2/20 0.48
SLC6A4 P31645 1/20 0.48
CDK4 P11802 1/20 0.47
CCND1 P24385 1/20 0.47
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
MAOA P21397 1/20 0.47
ADRA1D P25100 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5165988 0.99 OPRL1 (0.69) OPRL1OPRM1HTR1AHTR2AHTR2C
SCHEMBL1969237 0.85 HTR2A (0.68) HTR1AHTR2AHTR2CHTR2BALDH1A1
SCHEMBL5163716 0.81 OPRL1 (1.00) OPRL1OPRM1HTR1AHTR2AALDH1A1
Hydrochloric Acid SCHEMBL5165408 0.80 OPRL1 (1.00) OPRL1OPRM1HTR1AHTR2AALDH1A1
Hydrochloric Acid SCHEMBL302608 0.79 OPRL1 (0.58) OPRL1OPRM1HTR1AHTR2AHTR2C
SCHEMBL5343485 0.79 OPRL1 (0.74) OPRL1OPRM1HTR1AHTR2AALDH1A1
Hydrochloric Acid SCHEMBL5336823 0.78 OPRL1 (0.74) OPRL1OPRM1HTR1AHTR2AALDH1A1
SCHEMBL3808133 0.78 OPRL1 (0.60) OPRL1OPRM1HTR1AHTR2AHTR2C
SCHEMBL5165865 0.78 OPRL1 (1.00) OPRL1OPRM1ALDH1A1LMNASMN1; SMN2
SCHEMBL4857906 0.78 OPRL1 (0.65) OPRL1OPRM1HTR1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392641-B1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2007-04-11 EP claimed
US-7276518-B2 Substituted cyclohexane-1,4-diamine compounds GRUENENTHAL GMBH (DE) 2007-10-02 US disclosed
EP-1392641-B1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2007-04-11 EP disclosed
US-20040229872-A1 Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity GRUENENTHAL GMBH (DE) 2004-11-18 US disclosed
US-20040162287-A1 Substituted cyclohexane-1,4-diamine compounds GRUENENTHAL GMBH (DE) 2004-08-19 US disclosed
EP-1392641-A1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2004-03-03 EP disclosed
EP-1385493-A1 SUBSTITUTED CYCLOHEXAN-1,4-DIAMINE DERIVATIVES WITH CONSTIPATING AND PERIPHERAL ANALGESIC PROPERTIES Grünenthal GmbH (DE) 2004-02-04 EP disclosed
WO-2002090317-A1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2002-11-14 WO disclosed
WO-2002089783-A1 SUBSTITUTED CYCLOHEXAN-1,4-DIAMINE DERIVATIVES WITH CONSTIPATING AND PERIPHERAL ANALGESIC PROPERTIES Grünenthal GmbH (DE) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162287-A1 Substituted cyclohexane-1,4-diamine compounds DPYD, DDC, QDPR OPRL1 1102/4885OPRM1 459/4885HTR1A 200/4885
US-20040229872-A1 Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity ARG1, CD2, PDCD1 OPRL1 41/4885OPRM1 250/4885HTR1A 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.